Source: Health Products Regulatory Authority (IE) Revision Year: 2021 Publisher: GlaxoSmithKline (Ireland) Limited, 12 Riverwalk, Citywest Business Campus, Dublin 24, Ireland
Becotide Evohaler 50 micrograms, Pressurised Inhalation Solution.
| Pharmaceutical Form |
|---|
|
Pressurised Inhalation, Solution. Clear and colourless solution in an aluminium canister with a valve. |
One metered dose contains 50 micrograms of Beclometasone Dipropionate.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Beclometasone |
Beclometasone is a pro-drug with weak glucocorticoid receptor binding affinity. It is extensively hydrolysed via esterase enzymes to the active metabolite beclometasone-17-monopropionate (B-17-MP), which has potent topical anti-inflammatory activity. |
| List of Excipients |
|---|
|
Norflurane (Hydrofluoroalkane (HFA) 134a) |
The inhaler comprises an aluminium can fitted with a 50 microlitre metering valve, plastic actuator and dust cap. Each canister contains 200 metered doses.
GlaxoSmithKline (Ireland) Limited, 12 Riverwalk, Citywest Business Campus, Dublin 24, Ireland
PA1077/042/006
Date of first authorisation: 07 January 2005
Date of last renewal: 07 January 2010
| Drug | Countries | |
|---|---|---|
| BECOTIDE | Spain, France, Ireland, Italy, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
